Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma (PASSAGE)

The PASSAGE Study will investigate how Tezepelumab (TEZSPIRE®) works in people with severe asthma and in under-represented populations, the information we collect might help others with asthma in the future. The time commitment for the PASSAGE Study is about a year. Patients will be asked to attend monthly study visits to receive the study drug injections. Study visits will also consist of lung function tests, blood draws, and patients will be asked to fill in questionnaires at different times through the duration of the study. Tezepelumab (TEZSPIRE®) is currently approved in the US for adults and adolescents aged 12 years and older.